

Supplement: Association of demographic and clinical characteristics with mean VA

Characteristic		N (%) at Baseline	ETDRS Equivalent Lines of Visual Acuity (95% CI)	p-value
Uveitis Location	Anterior	4525 (51%)	reference	<0.001
	Intermediate	1658 (19%)	-0.70 (-0.42, -0.98)	
	Posterior	1605 (18%)	-2.2 (-1.9, -2.5)	
	Panuveitis	1011 (11%)	-2.3 (-2.0, -2.6)	
Race/Ethnicity*	White	6457 (73%)	reference	<0.001
	Black	1317 (15%)	-0.19 (+0.10, -0.48)	
	Hispanic	380 (4%)	-1.1 (-0.60, -1.6)	
	Other	645 (7%)	+0.23 (+0.61, -0.14)	
Smoking	Never	5113 (58%)	reference	<0.001
	Past	929 (11%)	-0.22 (+0.11, -0.55)	
	Current	1486 (17%)	-0.99 (-0.71, -1.3)	
	Unknown†	1271 (14%)	+0.32 (+0.66, -0.03)	
Gender	Male	3097 (35%)	+0.01 (+0.21, -0.20)	0.93
	Female	5702 (65%)	reference	
Age	<18	1104 (13%)	+0.16 (+0.54, -0.21)	<0.001
	18-25	720 (8%)	-0.28 (+0.12, -0.68)	
	26-35	1596 (18%)	+0.03 (+0.34, -0.27)	
	36-45	1878 (21%)	reference	
	46-55	1673 (19%)	-0.17 (+0.13, -0.47)	
	56-65	1008 (11%)	-0.53 (-0.18, -0.89)	
	>65	820 (9%)	-1.9 (-1.5, -2.3)	
Behçet Disease	No	8575 (97%)	reference	<0.001
	Yes	224 (3%)	-1.0 (-0.42, -1.7)	
Sarcoidosis	No	8198 (93%)	reference	0.04
	Yes	601 (7%)	+0.40 (+0.78, +0.01)	
Juvenile idiopathic arthritis (JIA)	No	8388 (95%)	reference	0.13
	Yes	411 (5%)	-0.39 (+0.12, -0.90)	
Spondyloarthropathy	No	8381 (95%)	reference	0.22
	Yes	418 (5%)	-0.30 (+0.17, -0.76)	
Inflammatory Bowel Disease (IBD)**	No	8570 (97%)	reference	0.27
	Yes	229 (3%)	+0.34 (+0.95, -0.26)	

Other Systemic Inflammatory Disease	No	8432 (96%)	reference	0.11
	Yes	367 (4%)	-0.39 (+0.09, -0.87)	
Prior Cataract Surgery	Never	7785 (88%)	reference	<0.001
	Prior to Baseline	1014 (12%)	-3.0 (-2.6, -3.3)	
	During Follow-up	0 (0%) ^{*****}	+2.9 (+3.0, +2.7)	
Prior Glaucoma Surgery	No	8626 (98%)	reference	<0.001
	Yes	173 (2%)	-0.68 (-0.44, -0.91)	
Prior Retinal Detachment Surgery	No	8721 (99%)	reference	<0.001
	Yes	78 (1%)	-3.6 (-3.1, -4.2)	
Prior Pars Plana Vitrectomy (not for retinal detachment)	No	8548 (97%)	reference	<0.001
	Yes	251 (3%)	-1.3 (-1.1, -1.5)	
Duration of Uveitis Prior to Presentation for Tertiary Uveitis Care	≤6 months	3017 (34%)	reference	<0.001
	>6 months to 2 years	2009 (23%)	-0.35 (-0.09, -0.61)	
	>2 to 5 years	1592 (18%)	-0.53 (-0.25, -0.81)	
	≥5 years	2181 (25%)	-1.2 (-0.90, -1.4)	
Anterior Chamber Cells	Quiet	5145 (58%)	reference	<0.001
	0.5+	1470 (17%)	-0.20 (-0.12, -0.28)	
	1+	1043 (12%)	-0.45 (-0.34, -0.55)	
	2+ or worse	1141 (13%)	-1.0 (-0.89, -1.1)	
Vitreous Cells	Quiet	4927 (56%)	reference	<0.001
	0.5+	1190 (14%)	+0.18 (+0.26, +0.09)	
	1+	1412 (16%)	-0.10 (-0.007, -0.20)	
	2+ or worse	1270 (14%)	-0.59 (-0.47, -0.72)	
Vitreous Haze ^{***}	Quiet	6881 (78%)	reference	<0.001
	1+	956 (11%)	-0.40 (-0.29, -0.50)	
	2+	350 (4%)	-1.5 (-1.3, -1.7)	
	3+ or worse	107 (1%)	-4.2 (-3.9, -4.6)	
	Missing [†]	505 (6%)	-0.89 (-0.61, -1.2)	
Intraocular Pressure	≤5 mm Hg	98 (1%)	-2.5 (-2.3, -2.8)	<0.001
	6-23 mm Hg	7743 (88%)	reference	
	24-29 mm Hg	339 (4%)	-0.19 (-0.05, -0.33)	
	≥30	213 (2%)	-0.34 (-0.15, -0.53)	
	Missing [†]	406 (5%)	-0.89 (-0.59, -1.2)	
Posterior Synechiae, Any	No	7514 (85%)	reference	<0.001
	Yes	1285 (15%)	-0.46 (-0.34, -0.57)	

Peripheral Anterior Synechiae, Any	No	8527 (97%)	reference	<0.01
	Yes	272 (3%)	-0.42 (-0.17, -0.68)	
Band Keratopathy, Any	No	7087 (81%)	reference	<0.001
	Yes	240 (3%)	-0.41 (-0.15, -0.68)	
	Missing [†]	1472 (17%)	+0.45 (+0.68, +0.22)	
Macular Edema	No	7490 (85%)	reference	<0.001
	Yes	1309 (15%)	-0.90 (-0.81, -0.99)	
Epiretinal Membrane	No	8321 (95%)	reference	0.89
	Yes	478 (5%)	-0.008 (+0.10, -0.12)	
Choroidal Neovascularization	No	8725 (99%)	reference	<0.001
	Yes	74 (1%)	-1.8 (-1.3, -2.2)	
Snowbanking ^{****}	No	8407 (96%)	reference	0.46
	Yes	392 (4%)	-0.09 (+0.14, -0.31)	
Retinal Vascular Sheathing	No	8089 (92%)	reference	0.02
	Yes	710 (8%)	+0.17 (+0.31, +0.03)	
Retinal Vascular Occlusion	No	8737 (99%)	reference	0.41
	Yes	62 (1%)	-0.19 (+0.26, -0.64)	

[†] Patients with any missing data at baseline were generally not included in the analysis, but band keratopathy (17%), smoking status (14%), intraocular pressure (IOP, 5%), and vitreous haze (6%) were missing enough baseline measurements to warrant respective separate missing categories

* Hispanic includes all patients with Hispanic ethnicity

** IBD includes ulcerative colitis and Crohn's disease

*** 0.5+ was not used for vitreous haze due to a database error; it was instead coded as either Quiet or 1+

**** Snowbanking may have reflected either active exudation or residual fibrosis

***** By definition no patients could have had cataract surgery during follow-up before beginning follow-up; 206 (2.3%) of the eyes had cataract surgery performed during follow-up